GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sinclair Pharma PLC (XPAR:SPH) » Definitions » Price-to-Owner-Earnings

Sinclair Pharma (XPAR:SPH) Price-to-Owner-Earnings : (As of Jun. 19, 2024)


View and export this data going back to . Start your Free Trial

What is Sinclair Pharma Price-to-Owner-Earnings?

As of today (2024-06-19), Sinclair Pharma's share price is €0.27. Sinclair Pharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Sinclair Pharma's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Sinclair Pharma was 11.84. The lowest was 0.00. And the median was 8.16.


XPAR:SPH's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 24.73
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-19), Sinclair Pharma's share price is €0.27. Sinclair Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2018 was €0.00. Therefore, Sinclair Pharma's PE Ratio for today is N/A.

As of today (2024-06-19), Sinclair Pharma's share price is €0.27. Sinclair Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was €0.00. Therefore, Sinclair Pharma's PE Ratio without NRI for today is N/A.

During the past 13 years, Sinclair Pharma's highest PE Ratio without NRI was 17.22. The lowest was 0.00. And the median was 7.50.


Sinclair Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for Sinclair Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinclair Pharma Price-to-Owner-Earnings Chart

Sinclair Pharma Annual Data
Trend Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Dec17
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sinclair Pharma Semi-Annual Data
Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Jun17 Dec17 Jun18
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sinclair Pharma's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Sinclair Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sinclair Pharma's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sinclair Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Sinclair Pharma's Price-to-Owner-Earnings falls into.



Sinclair Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Sinclair Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.27/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinclair Pharma  (XPAR:SPH) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Sinclair Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Sinclair Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinclair Pharma (XPAR:SPH) Business Description

Traded in Other Exchanges
N/A
Address
Sinclair Pharma PLC is a United Kingdom-based specialty pharmaceutical company focused on Dermatology, in particular, Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on key emerging markets through long-term multi-product, multi-country, sales & marketing and distribution deals with key strategic partners. The Company's reportable operating segments are International Operations, France, Italy, Germany, UK, and Spain.